ClinicalTrials.gg
Active, not recruitingNCT02736656Updated Nov 17, 2026

Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)

A Phase 3 interventional study of SPN-812 in Attention-Deficit/Hyperactivity Disorder, sponsored by Supernus Pharmaceuticals, Inc.. Active, not recruiting at 16 sites in United States. Open to participants aged 4 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Supernus Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

Updated Nov 17, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,400
Allocation
Not applicable
Ages
4 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 12 studies testing viloxazine in Attention Deficit Disorder with Hyperactivity — 1 open to participants now, 2 under way, 1 of them phase 3. Viloxazine · Attention Deficit Disorder with Hyperactivity.

Planned enrollment
Largest of 12
1,400 · median 292
Started
2016
with 1 other
Phase 3
8 of 12
none open now
Registered
2nd of 12
by date
Lead sponsor
12 of 12
Supernus Pharmaceuticals, Inc.

Among the 12 studies testing viloxazine in Attention Deficit Disorder with Hyperactivity, this one has the largest planned enrollment, is one of 2 that started in 2016, is one of 8 in phase 3, and was the 2nd registered.

Attention Deficit Disorder with Hyperactivity

1,818 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

1 of the 12 studies testing viloxazine in Attention Deficit Disorder with Hyperactivity is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About viloxazine

Viloxazine: first FDA approval 2021 (QELBREE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 4 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing viloxazine in Attention Deficit Disorder with Hyperactivity, or all of them as a file.
02

Study summary

Open label extension, long-term multicenter study of safety and efficacy of SPN-812 in pediatric ADHD patients

Read the detailed description

This is a multicenter open-label extension study assessing long term safety and efficacy of SPN-812 (viloxazine extended-release capsules) in pediatric subjects with ADHD who completed a randomized, double-blind, placebo-controlled clinical trial, including (A) a Phase 2 (Study 812P202: children 6 to 12 years of age) or a Phase 3 trial (Study 812P301 or 812P303: children 6 to 11 years of age; or Study 812P302 or 812P304: adolescents 12 to 17 years of age) or (B) a Phase 4 trial (Study 812P401: preschool-age children, 4-5 years of age). The study is divided into two phases, Optimization and Maintenance phases. Subjects in Cohort 'A' who completed a Phase 2 or Phase 3 trial followed protocol Schedule 'A' (exposure up to 72 months). Subjects in Cohort 'B' who complete the Phase 4 trial will follow Schedule 'B' (exposure up to 6 months).

03

Conditions studied

  • Attention-Deficit/Hyperactivity Disorder
04

Who can participate

Ages eligible
4 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Cohort 'A' Inclusion/Exclusion Criteria:

Inclusion Criteria 'A':

  1. Completion of a previous blinded study of SPN-812 for the treatment of ADHD.
  2. Continues to be medically healthy and with clinically normal laboratory profiles, vital signs, and (ECGs).
  3. Weight of at least 20 kg if 6-11 years old and at least 35 kg if 12 years or older.
  4. Written obtained from the subject's parent or legally authorized representative (LAR); and written Informed Assent obtained from the subject if appropriate; written Informed Consent obtained from the subject if he/she is 18 years old.
  5. Females of (FOCP) must be either sexually inactive (abstinent) or, if sexually active, must agree to use one of the following acceptable methods beginning 30 days prior to the first dose, throughout the study:

    1. simultaneous use of male condom and intra-uterine contraceptive device placed at least four weeks prior to the first study drug administration
    2. surgically sterile male partner
    3. simultaneous use of male condom and diaphragm with spermicide
    4. established hormonal contraceptive

Exclusion Criteria 'A':

  1. Current diagnosis of significant systemic disease or of a major psychiatric or neurological disorder, including history or family history of seizures or seizure-like disorders. History of Major Depressive Disorder is allowed if the subject is free of episodes currently and for the last six months.
  2. Current evidence of suicidal ideation and/or behaviors (assessed with Columbia Suicide Severity Rating Scale or C-SSRS).
  3. (BMI) greater than 95th percentile for the appropriate age and gender (according to the CDC BMI-for-Age Growth Charts for boys and girls).
  4. Pregnancy, breastfeeding, or refusal to practice contraception during the study for female subjects of childbearing potential (FOCP).
  5. Current substance or alcohol use.
  6. Any reason which, in the opinion of the Investigator, would prevent the subject from participating in the study.

Cohort 'B' Inclusion/Exclusion Criteria:

Inclusion Criteria 'B':

  1. Has completed a previous Study 812P401 and is less than 6 years of age at Visit 1 in this study (812P310).
  2. Continues to be medically healthy with clinically normal laboratory profiles, vital signs, and electrocardiograms.
  3. Weighs at least ≥5th percentile for age and sex.
  4. Parent or LAR is willing and able to provide Written Informed Consent.

Exclusion Criteria 'B':

  1. Has a current diagnosis of significant systemic disease and/or of a major psychiatric or neurological disorder.
  2. Current evidence of suicidal ideation and/or behaviors (assessed with Columbia Suicide Severity Rating Scale or C-SSRS), is at significant risk of suicide, either in the opinion of the Investigator or defined as a "yes" to suicidal ideation C-SSRS questions 4 or 5 or answering "yes" to suicidal behavior on the C-SSRS at Visit 1 or has attempted suicide from day of end of study in previous blinded study to day of Visit 1 in this study (812P310).
  3. Has a BMI >95th percentile for the appropriate age and sex (according to the CDC BMI-for-Age Growth Charts for boys and girls).
  4. Any reason which, in the opinion of the Investigator, would prevent the subject from participating in the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,400 participants (estimated)

Study arms

  • Experimental
    Open-Label Treatment

    Cohort 'A': Children and adolescents, 6-17 years of age, who completed a Phase 2 (Study 812P202) or Phase 3 (Study 812P301, 812P302, 812P303, or 812P304) randomized, double-blind, placebo-controlled clinical trial. Cohort 'B': Preschool-age children, 4-5 years of age, who completed a Phase 4 (Study 812P401) randomized, double-blind, placebo-controlled clinical trial.

    Drug: SPN-812

Interventions

  • Cohort 'A': Children 6-11 yrs of age take 100-400mg SPN-812 once daily by mouth and adolescents 12-17 yrs of age take 100-600mg SPN-812 once daily by mouth. Pediatric subjects in Cohort 'A' are given a choice to extend their participation in the study every 6 months for up to 72 months. Cohort 'B': Pre-school-age children 4-5 yrs of age take 100mg SPN-812 once daily by mouth. Pediatric subjects in Cohort 'B' will be treated with 100 mg SPN-812 (100 mg capsule) for up to 6 months.

    Also known as: viloxazine extended-release capsules

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events

    The incidence (percentage of subjects dosed) of adverse events by System Organ Class and Preferred term by cohort

    Time frame: up to 72 months

Secondary outcomes

  1. Trends in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHD-RS-IV-Preschool, ADHD-RS-IV or ADHD-RS-5) Score

    Change from Baseline in ADHD-RS Total score by visit by cohort

    Time frame: up to 72 months

  2. Trends in Clinical Global Impression-Improvement (CGI-I) scale score

    CGI-I score by visit by cohort

    Time frame: up to 72 months

07

Study locations

16 sites
  • Woodland International Research Group
    Little Rock, Arkansas 72211, United States
  • Alliance for Wellness dba Alliance for Research
    Long Beach, California 90807, United States
  • MCB Clinical Research Centers, LLC
    Colorado Springs, Colorado 80910, United States
  • Meridien Research at Florida Clinical Research Center
    Bradenton, Florida 34201, United States
  • Sarkis Clinical Trials
    Gainesville, Florida 32607, United States
  • Indago Research & Health Center, Inc.
    Hialeah, Florida 33012, United States
  • Florida Clinical Research Center, LLC.
    Maitland, Florida 32751, United States
  • Florida Clinical Research Center, LLC
    Maitland, Florida 32751, United States
  • IPS Research
    Oklahoma City, Oklahoma 73103, United States
  • Paradigm Research Professionals
    Oklahoma City, Oklahoma 73118, United States
  • Clinical Neuroscience Solutions, Inc.
    Memphis, Tennessee 38119, United States
  • CNS Healthcare
    Memphis, Tennessee 38119, United States
  • Bayou City Research Corporation
    Houston, Texas 77006, United States
  • Road Runner Research
    San Antonio, Texas 78258, United States
  • Ericksen Research & Development
    Clinton, Utah 84015, United States
  • Northwest Clinical Trials
    Bellevue, Washington 98004, United States
08

References and documents

Publications

  • Findling RL, Katic A, Liebowitz M, Waxmonsky J, Fry N, Qin P, Yarullina I, Maldonado-Cruz Z, Lieberman VR, Rubin J. Viloxazine Extended-Release Capsules in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: Results of a Long-Term, Phase 3, Open-Label Extension Trial. CNS Drugs. 2025 Nov;39(11):1157-1172. doi: 10.1007/s40263-025-01209-0. Epub 2025 Aug 13. PubMed 40802027 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2016 (actual). Primary completion is estimated for Dec 2026, 130 months after the start.

Of 66 industry-sponsored phase 3 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 19. This study's planned 130 months is above that.

Counting every sponsor, half of 80 studies reached it within 14 months; a quarter within 7 and three quarters within 32.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Sep 2026 → Dec 2026 and completion Sep 2026 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2016
First posted
Apr 13, 2016
StartActual
Feb 2, 2016
Primary completionEst.
Dec 2026was Sep 2026
CompletionEst.
Dec 2026was Sep 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 2026→Dec 2026
Nov 17, 2026
Study completion
Sep 2026→Dec 2026
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Primary completion Sep 2026→Dec 2026
    Study completion Sep 2026→Dec 2026

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02736656
Responsible party
Sponsor
First posted
Apr 13, 2016
Start date
Feb 2, 2016
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Nov 17, 2026

Study contacts

Jonathan Rubin, MD, MBA
study director · Supernus Pharmaceuticals, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Viloxazine

Start the discussion